207 related articles for article (PubMed ID: 22827519)
1. Towards isozyme-selective HDAC inhibitors for interrogating disease.
Gupta P; Reid RC; Iyer A; Sweet MJ; Fairlie DP
Curr Top Med Chem; 2012; 12(14):1479-99. PubMed ID: 22827519
[TBL] [Abstract][Full Text] [Related]
2. Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next.
Thaler F; Mercurio C
ChemMedChem; 2014 Mar; 9(3):523-6. PubMed ID: 24730063
[TBL] [Abstract][Full Text] [Related]
3. Discovery of macrocyclic HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation.
Yu W; Fells J; Clausen D; Liu J; Klein DJ; Christine Chung C; Myers RW; Wu J; Wu G; Howell BJ; Barnard RJO; Kozlowski J
Bioorg Med Chem Lett; 2021 Sep; 47():128168. PubMed ID: 34091041
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides.
Olsen CA; Ghadiri MR
J Med Chem; 2009 Dec; 52(23):7836-46. PubMed ID: 19705846
[TBL] [Abstract][Full Text] [Related]
5. Inside HDAC with HDAC inhibitors.
Bertrand P
Eur J Med Chem; 2010 Jun; 45(6):2095-116. PubMed ID: 20223566
[TBL] [Abstract][Full Text] [Related]
6. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, biological evaluation, and structural characterization of potent histone deacetylase inhibitors based on cyclic alpha/beta-tetrapeptide architectures.
Montero A; Beierle JM; Olsen CA; Ghadiri MR
J Am Chem Soc; 2009 Mar; 131(8):3033-41. PubMed ID: 19239270
[TBL] [Abstract][Full Text] [Related]
8. Innovative Strategies for Selective Inhibition of Histone Deacetylases.
Maolanon AR; Madsen AS; Olsen CA
Cell Chem Biol; 2016 Jul; 23(7):759-768. PubMed ID: 27447046
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent HDAC inhibitors based on chlamydocin with inhibitory effects on cell migration.
Wang S; Li X; Wei Y; Xiu Z; Nishino N
ChemMedChem; 2014 Mar; 9(3):627-37. PubMed ID: 24285590
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
Bürli RW; Luckhurst CA; Aziz O; Matthews KL; Yates D; Lyons KA; Beconi M; McAllister G; Breccia P; Stott AJ; Penrose SD; Wall M; Lamers M; Leonard P; Müller I; Richardson CM; Jarvis R; Stones L; Hughes S; Wishart G; Haughan AF; O'Connell C; Mead T; McNeil H; Vann J; Mangette J; Maillard M; Beaumont V; Munoz-Sanjuan I; Dominguez C
J Med Chem; 2013 Dec; 56(24):9934-54. PubMed ID: 24261862
[TBL] [Abstract][Full Text] [Related]
11. Design of selective histone deacetylase inhibitors: rethinking classical pharmacophore.
Melesina J; Praetorius L; Simoben CV; Robaa D; Sippl W
Future Med Chem; 2018 Jul; 10(13):1537-1540. PubMed ID: 29966452
[TBL] [Abstract][Full Text] [Related]
12. Natural and Synthetic Macrocyclic Inhibitors of the Histone Deacetylase Enzymes.
Maolanon AR; Kristensen HM; Leman LJ; Ghadiri MR; Olsen CA
Chembiochem; 2017 Jan; 18(1):5-49. PubMed ID: 27748555
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
Tashima T; Murata H; Kodama H
Bioorg Med Chem; 2014 Jul; 22(14):3720-31. PubMed ID: 24864038
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors.
De Vreese R; D'hooghe M
Eur J Med Chem; 2017 Jul; 135():174-195. PubMed ID: 28453994
[TBL] [Abstract][Full Text] [Related]
15. Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach.
Hsu KC; Liu CY; Lin TE; Hsieh JH; Sung TY; Tseng HJ; Yang JM; Huang WJ
Sci Rep; 2017 Jun; 7(1):3228. PubMed ID: 28607401
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylases (HDAC) in physiological and pathological bone remodelling.
Cantley MD; Zannettino ACW; Bartold PM; Fairlie DP; Haynes DR
Bone; 2017 Feb; 95():162-174. PubMed ID: 27913271
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of novel FK228 analogues as potential isoform selective HDAC inhibitors.
Narita K; Matsuhara K; Itoh J; Akiyama Y; Dan S; Yamori T; Ito A; Yoshida M; Katoh T
Eur J Med Chem; 2016 Oct; 121():592-609. PubMed ID: 27318982
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
Muthyala R; Shin WS; Xie J; Sham YY
Bioorg Med Chem Lett; 2015 Oct; 25(19):4320-4. PubMed ID: 26264503
[TBL] [Abstract][Full Text] [Related]
19. From natural products to HDAC inhibitors: An overview of drug discovery and design strategy.
Qiu X; Zhu L; Wang H; Tan Y; Yang Z; Yang L; Wan L
Bioorg Med Chem; 2021 Dec; 52():116510. PubMed ID: 34826681
[TBL] [Abstract][Full Text] [Related]
20. The antileishmanial activity of isoforms 6- and 8-selective histone deacetylase inhibitors.
Sodji Q; Patil V; Jain S; Kornacki JR; Mrksich M; Tekwani BL; Oyelere AK
Bioorg Med Chem Lett; 2014 Oct; 24(20):4826-30. PubMed ID: 25240614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
